Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT03162055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)
Study identification
- NCT ID
- NCT03162055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 1,119 participants
Conditions and interventions
Conditions
Interventions
- Glycopyrronium/Formoterol Fumarate Drug
- umeclidinium/vilanterol Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2017
- Primary completion
- May 3, 2018
- Completion
- May 3, 2018
- Last update posted
- May 21, 2019
2017 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tempe | Arizona | 85283 | — |
| Research Site | Escondido | California | 92025 | — |
| Research Site | Sacramento | California | 95821 | — |
| Research Site | Hollywood | Florida | 33021 | — |
| Research Site | Lawrenceville | Georgia | 30046 | — |
| Research Site | Rincon | Georgia | 31326 | — |
| Research Site | Farmington Hills | Michigan | 48336 | — |
| Research Site | The Bronx | New York | 10455 | — |
| Research Site | Gastonia | North Carolina | 28054 | — |
| Research Site | Dublin | Ohio | 43016 | — |
| Research Site | Pittsburgh | Pennsylvania | 15243 | — |
| Research Site | Greenville | South Carolina | 29615 | — |
| Research Site | Spartanburg | South Carolina | 29303 | — |
| Research Site | Sherman | Texas | 75092 | — |
| Research Site | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03162055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2019 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03162055 live on ClinicalTrials.gov.